Improving CAR-T cell therapy for children with relapsed B-cell leukemia
Inhibiting Free Fatty Acid Transport to Improve CAR-T Cell Therapy of Relapsed B-cell Acute Lymphoblastic Leukemia
This study is looking at how blocking certain fatty acids might make CAR-T cell therapy work better for kids and young adults with relapsed B-cell leukemia, especially those with specific gene changes, to help them get better when other treatments haven't worked.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11016165 on NIH RePORTER |
What this research studies
This research investigates how inhibiting the transport of free fatty acids can enhance the effectiveness of CAR-T cell therapy in treating relapsed B-cell acute lymphoblastic leukemia (B-ALL) in children and young adults. The study focuses on understanding the mechanisms of resistance to CAR-T therapy, particularly in cases with TP53 mutations. By using advanced techniques like CRISPR/Cas9 screening, researchers aim to identify specific fatty acid transporters that, when inhibited, could improve patient outcomes. The goal is to provide a more effective treatment option for patients who have not responded to traditional therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and young adults diagnosed with relapsed B-cell acute lymphoblastic leukemia, particularly those with chemotherapy-resistant cases.
Not a fit: Patients who do not have B-cell acute lymphoblastic leukemia or those who are not relapsed or refractory to existing therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and treatment responses for children and young adults with relapsed B-ALL.
How similar studies have performed: Previous research has shown promise in enhancing CAR-T cell therapy through metabolic interventions, suggesting that this approach may yield significant advancements.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Witkowski, Matthew — University of Colorado Denver
- Study coordinator: Witkowski, Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.